236 related articles for article (PubMed ID: 34252262)
21. Development of immune gene pair-based signature predictive of prognosis and immunotherapy in esophageal cancer.
Cao K; Ma T; Ling X; Liu M; Jiang X; Ma K; Zhu J; Ma J
Ann Transl Med; 2021 Oct; 9(20):1591. PubMed ID: 34790797
[TBL] [Abstract][Full Text] [Related]
22. A prognostic signature based on immune-related genes for cervical squamous cell carcinoma and endocervical adenocarcinoma.
Liu J; Wu Z; Wang Y; Nie S; Sun R; Yang J; Cheng W
Int Immunopharmacol; 2020 Nov; 88():106884. PubMed ID: 32795900
[TBL] [Abstract][Full Text] [Related]
23. A Seven-Gene Signature with Close Immune Correlation Was Identified for Survival Prediction of Lung Adenocarcinoma.
Zou X; Hu Z; Huang C; Chang J
Med Sci Monit; 2020 Jul; 26():e924269. PubMed ID: 32613949
[TBL] [Abstract][Full Text] [Related]
24. Immune Infiltration Subtypes Characterization and Identification of Prognosis-Related lncRNAs in Adenocarcinoma of the Esophagogastric Junction.
Hu X; Wu L; Liu B; Chen K
Front Immunol; 2021; 12():651056. PubMed ID: 34122409
[TBL] [Abstract][Full Text] [Related]
25. Identification and validation of an immune prognostic signature in colorectal cancer.
Li M; Wang H; Li W; Peng Y; Xu F; Shang J; Dong S; Bu L; Wang H; Wei W; Hu Q; Liu L; Zhao Q
Int Immunopharmacol; 2020 Nov; 88():106868. PubMed ID: 32771948
[TBL] [Abstract][Full Text] [Related]
26. A N
Mei W; Jia X; Xin S; Liu X; Jin L; Sun X; Zhang JX; Zhang B; Yang G; Chen P; Ye L
J Oncol; 2022; 2022():8604216. PubMed ID: 35602299
[TBL] [Abstract][Full Text] [Related]
27. The tumor immune microenvironment and immune-related signature predict the chemotherapy response in patients with osteosarcoma.
He L; Yang H; Huang J
BMC Cancer; 2021 May; 21(1):581. PubMed ID: 34016089
[TBL] [Abstract][Full Text] [Related]
28. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
[TBL] [Abstract][Full Text] [Related]
29. Database Mining of Genes of Prognostic Value for the Prostate Adenocarcinoma Microenvironment Using the Cancer Gene Atlas.
Zhao X; Hu D; Li J; Zhao G; Tang W; Cheng H
Biomed Res Int; 2020; 2020():5019793. PubMed ID: 32509861
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value and potential function of splicing events in prostate adenocarcinoma.
Huang ZG; He RQ; Mo ZN
Int J Oncol; 2018 Dec; 53(6):2473-2487. PubMed ID: 30221674
[TBL] [Abstract][Full Text] [Related]
31. A Novel Inflammatory-Related Gene Signature Based Model for Risk Stratification and Prognosis Prediction in Lung Adenocarcinoma.
Zhai WY; Duan FF; Chen S; Wang JY; Lin YB; Wang YZ; Rao BY; Zhao ZR; Long H
Front Genet; 2021; 12():798131. PubMed ID: 35069695
[TBL] [Abstract][Full Text] [Related]
32. Identification and validation of an immune-related gene signature predictive of overall survival in colon cancer.
Zhang X; Zhao H; Shi X; Jia X; Yang Y
Aging (Albany NY); 2020 Dec; 12(24):26095-26120. PubMed ID: 33401247
[TBL] [Abstract][Full Text] [Related]
33. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
[TBL] [Abstract][Full Text] [Related]
34. Predictive postoperative model for biochemical recurrence in patients with localized prostate cancer treated with radical prostatectomy as monotherapy.
Molina Escudero R; Herranz-Amo F; Paez-Borda A; Hernandez Fernandez C
Arch Esp Urol; 2014 Apr; 67(3):259-67. PubMed ID: 24840591
[TBL] [Abstract][Full Text] [Related]
35. A Novel Set of Immune-associated Gene Signature predicts Biochemical Recurrence in Localized Prostate Cancer Patients after Radical Prostatectomy.
Luan JC; Zhang QJ; Zhao K; Zhou X; Yao LY; Zhang TT; Zeng TY; Xia JD; Song NH
J Cancer; 2021; 12(12):3715-3725. PubMed ID: 33995646
[No Abstract] [Full Text] [Related]
36. Prediction of prostate-specific antigen recurrence in men with long-term follow-up postprostatectomy using quantitative nuclear morphometry.
Veltri RW; Miller MC; Isharwal S; Marlow C; Makarov DV; Partin AW
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):102-10. PubMed ID: 18199716
[TBL] [Abstract][Full Text] [Related]
37. RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy.
Strand SH; Switnicki M; Moller M; Haldrup C; Storebjerg TM; Hedegaard J; Nordentoft I; Hoyer S; Borre M; Pedersen JS; Wild PJ; Park JY; Orntoft TF; Sorensen KD
Oncotarget; 2017 Jan; 8(4):5774-5788. PubMed ID: 28052017
[TBL] [Abstract][Full Text] [Related]
38. A signature of seven immune-related genes predicts overall survival in male gastric cancer patients.
Xu X; Lu Y; Wu Y; Wang M; Wang X; Wang H; Chen B; Li Y
Cancer Cell Int; 2021 Feb; 21(1):117. PubMed ID: 33602220
[TBL] [Abstract][Full Text] [Related]
39. Roles of m5C RNA Modification Patterns in Biochemical Recurrence and Tumor Microenvironment Characterization of Prostate Adenocarcinoma.
Xu Z; Chen S; Zhang Y; Liu R; Chen M
Front Immunol; 2022; 13():869759. PubMed ID: 35603206
[TBL] [Abstract][Full Text] [Related]
40. Comparison of robot-assisted and open retropubic radical prostatectomy for risk of biochemical progression in men with positive surgical margins.
Shapiro EY; Scarberry K; Patel T; Bergman A; Ahn JJ; Sahi N; RoyChoudhury A; Deutch I; McKiernan JM; Benson MC; Badani KK
J Endourol; 2014 Feb; 28(2):208-13. PubMed ID: 24044423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
